Abstract:Neurodegenerative diseases (NDs) such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) are devastating conditions that can develop without noticeable symptoms, causing irreversible damage to neurons before any signs become clinically evident. NDs are a major cause of disability and mortality worldwide. Currently, there are no cures or treatments to halt their progression. Therefore, the development of early detection methods is urgently needed to delay neuronal loss as soon as possible. Despite advancements in Medtech, the early diagnosis of NDs remains a challenge at the intersection of medical, IT, and regulatory fields. Thus, this review explores "digital biomarkers" (tools designed for remote neurocognitive data collection and AI analysis) as a potential solution. The review summarizes that recent studies combining AI with digital biomarkers suggest the possibility of identifying pre-symptomatic indicators of NDs. For instance, research utilizing convolutional neural networks for eye tracking has achieved significant diagnostic accuracies. ROC-AUC scores reached up to 0.88, indicating high model performance in differentiating between PD patients and healthy controls. Similarly, advancements in facial expression analysis through tools have demonstrated significant potential in detecting emotional changes in ND patients, with some models reaching an accuracy of 0.89 and a precision of 0.85. This review follows a structured approach to article selection, starting with a comprehensive database search and culminating in a rigorous quality assessment and meaning for NDs of the different methods. The process is visualized in 10 tables with 54 parameters describing different approaches and their consequences for understanding various mechanisms in ND changes. However, these methods also face challenges related to data accuracy and privacy concerns. To address these issues, this review proposes strategies that emphasize the need for rigorous validation and rapid integration into clinical practice. Such integration could transform ND diagnostics, making early detection tools more cost-effective and globally accessible. In conclusion, this review underscores the urgent need to incorporate validated digital health tools into mainstream medical practice. This integration could indicate a new era in the early diagnosis of neurodegenerative diseases, potentially altering the trajectory of these conditions for millions worldwide. Thus, by highlighting specific and statistically significant findings, this review demonstrates the current progress in this field and the potential impact of these advancements on the global management of NDs.

Neurodegenerative Diseases: The Value of Early Predictive End Points

Biomarkers for Managing Neurodegenerative Diseases

Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases

Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease

Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases

Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage

Alzheimer's disease biomarkers and their current use in clinical research and practice

The Potential of Metabolomics to Find Proper Biomarkers for Addressing the Neuroprotective Efficacy of Drugs Aimed at Delaying Parkinson's and Alzheimer's Disease Progression

Functional Neurophysiological Biomarkers of Early‐Stage Alzheimer’s Disease: An Experimental Perspective of Network Hyperexcitability in Disease Progression and Pharmacological Interventions

The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Biomarkers for neurodegenerative diseases

Use of biomarkers in clinical trials and future developments that will help identify novel biomarkers

The Potential of Circulating Cell-Free DNA in Precision Neurology

Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression

Biomarker-Based Precision Therapy for Alzheimer's Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine

Paths to Alzheimer’s disease prevention: From modifiable risk factors to biomarker enrichment strategies

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis

The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis